| Name | Title | Contact Details |
|---|---|---|
Ehab Esmail |
Vice President, Global Regulatory, Quality, and Clinical | Profile |
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Genvion Corporation is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Dainippon Sumitomo Pharma America Holdings is a Fort Lee, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ITM Isotopen Technologien München AG and its subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.